🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to scientists.

An International Public Health Issue

Gonorrhoea infections are escalating globally, with figures suggesting more than 82 million instances per year. Particularly high rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the reality of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options presently on offer.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has designated it as a "critical concern". A tracking program revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Receive Authorization

One new antibiotic, alternatively called a brand name, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Scientists hope that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, also received approval in concurrent days. This treatment, which is also used to treat UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The charitable organization GARDP worked alongside the drug firm its industry partner to see it through.

“This approval signifies a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Testing Outcomes and Worldwide Availability

As per results detailed in a prominent scientific publication, the new drug eradicated over nine in ten of cases of the STI. This places it at an equal footing with the current standard treatment, which combines a dual-drug approach. The trial enrolled hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the authority to license and sell the drug in many regions with limited resources.

Doctors directly involved have voiced positive views. Access to a easy-to-administer therapy such as this is hailed as a "critical tool" for managing the epidemic. This is considered vital to reduce the burden of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea globally.